Martin Madden - Microbot Medical Independent Director
| CY9D Stock | EUR 0.92 0.01 1.08% |
Insider
Martin Madden is Independent Director of Microbot Medical since 2017.
| Age | 57 |
| Tenure | 7 years |
| Phone | 781 875 3605 |
| Web | https://www.microbotmedical.com |
Microbot Medical Management Efficiency
The company has return on total asset (ROA) of (0.6524) % which means that it has lost $0.6524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1989) %, meaning that it generated substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Frans Heerden | Astral Foods Limited | 42 | |
| Daniel Fachner | JJ SNACK FOODS | 63 | |
| Bcompt Bcom | Astral Foods Limited | 67 | |
| Andres Daroch | Austevoll Seafood ASA | 63 | |
| Louis Vermaas | Astral Foods Limited | 51 | |
| Colin Smith | Astral Foods Limited | 62 | |
| Esteban Alert | Austevoll Seafood ASA | 71 | |
| Soo Yoon | LG Display Co | 58 | |
| Mary Kehoe | JJ SNACK FOODS | N/A | |
| Leonie Marupen | Astral Foods Limited | 51 | |
| Arne Mogster | Austevoll Seafood ASA | 48 | |
| Douglas Davidson | JJ SNACK FOODS | N/A | |
| Colin Day | PREMIER FOODS | 64 | |
| HoYoung Jeong | LG Display Co | 62 | |
| Evert Potgieter | Astral Foods Limited | 53 | |
| Adriana Alva | Austevoll Seafood ASA | 60 | |
| Britt Drivenes | Austevoll Seafood ASA | 60 | |
| Ken Plunk | JJ SNACK FOODS | 60 | |
| Bum Kim | LG Display Co | 56 | |
| Tore Mohn | Austevoll Seafood ASA | 73 | |
| Michael Pollner | JJ SNACK FOODS | 50 | |
Management Performance
| Return On Equity | -1.2 | |||
| Return On Asset | -0.65 |
Microbot Medical Leadership Team
Elected by the shareholders, the Microbot Medical's board of directors comprises two types of representatives: Microbot Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Microbot. The board's role is to monitor Microbot Medical's management team and ensure that shareholders' interests are well served. Microbot Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Microbot Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Prattipati Laxminarain, Independent Director | ||
| Yoav Waizer, Independent Director | ||
| Simon Sharon, Chief Technology Officer | ||
| Rachel Vaknin, Chief Officer | ||
| Harel Gadot, Chairman of the Board, President, Chief Executive Officer | ||
| Tal Wenderow, Independent Director | ||
| Yoseph Bornstein, Independent Director | ||
| Eyal MD, Chief Board | ||
| Aileen Stockburger, Independent Director | ||
| MSc MBA, CTO GM | ||
| Pr DSc, Scientific CoFounder | ||
| David Naim, Chief Financial Officer | ||
| Eyal Morag, Chief Medical Officer | ||
| Scott Burell, Independent Director | ||
| Martin Madden, Independent Director |
Microbot Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Microbot Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.2 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | 25.69 M | |||
| Shares Outstanding | 7.89 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.65 % | |||
| Price To Book | 5.90 X | |||
| EBITDA | (11.28 M) | |||
| Net Income | (11.31 M) | |||
| Cash And Equivalents | 20.62 M |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Microbot Stock
When determining whether Microbot Medical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Microbot Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Microbot Medical Stock. Highlighted below are key reports to facilitate an investment decision about Microbot Medical Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Microbot Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Microbot Stock please use our How to Invest in Microbot Medical guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.